

# Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

## Charles River Laboratories

RRID:SCR\_003792

Type: Tool

### Proper Citation

Charles River Laboratories (RRID:SCR\_003792)

### Resource Information

**URL:** <http://www.criver.com/>

**Proper Citation:** Charles River Laboratories (RRID:SCR\_003792)

**Description:** Commercial organism provider selling mice, rats and other model animals. American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. (Wikipedia)

**Abbreviations:** CRL

**Synonyms:** Charles River Laboratories Inc., Charles River, Charles River Laboratories International Inc.

**Resource Type:** biomaterial supply resource, material resource, organism supplier

**Keywords:** RIN, Resource Information Network, pre-clinical, clinical, pharmaceutical, medical device, biotechnology, drug, drug discovery, RRID Community Authority

**Resource Name:** Charles River Laboratories

**Resource ID:** SCR\_003792

**Alternate IDs:** SCR\_013551, grid.452317.6, nlx\_158088, nif-0000-00462, Wikidata: Q28974283

**Alternate URLs:** <https://ror.org/01tasya06>

**License:** Resource specific license

**License URLs:** <https://www.criver.com/about-us/terms-conditions>

**Record Creation Time:** 20220129T080221+0000

## Ratings and Alerts

No rating or validation information has been found for Charles River Laboratories.

No alerts have been found for Charles River Laboratories.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 11489 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Rawi R, et al. (2025) The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody. Structure (London, England : 1993).

Contreras GA, et al. (2025) Perivascular Adipocytes' Adipogenesis Is Defined by Their Anatomical Location in the Descending Thoracic Aorta. Cells, 14(8).

Pontes AP, et al. (2025) In vitro and in vivo delivery of mRNA to joint cells using polymeric nanoparticles. Acta biomaterialia, 202, 418.

Zidel A, et al. (2025) Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. Scientific reports, 15(1), 16964.

Zhang C, et al. (2025) NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studies. Frontiers in medicine, 12, 1592693.

Kaplan HS, et al. (2025) Sensory input, sex and function shape hypothalamic cell type development. Nature.

Sanches ES, et al. (2025) Methylphenidate triggers retinal oxidative stress and mitochondrial dysfunction under physiological conditions but has beneficial effects in inflammatory settings. Neuropharmacology, 279, 110623.

Olaitan G, et al. (2025) Focused Ultrasound Modulates Dopamine in a Mesolimbic Reward Circuit. Journal of neurochemistry, 169(2), e70001.

Cluzet V, et al. (2025) Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways. Molecular cancer therapeutics, 24(8), 1197.

Rahman NA, et al. (2025) Targeted destruction of follicle stimulating hormone receptor-positive cancer cells in vitro and in vivo by a lytic peptide Phor21-FSH? conjugate. Molecular medicine (Cambridge, Mass.), 31(1), 224.

Shmuel S, et al. (2025) Imaging and targeting S1PR1 in HER2+ tumors. Nuclear medicine and biology, 148-149, 109057.

Cheng VWT, et al. (2025) ARHGAP12 and ARHGAP29 exert distinct regulatory effects on switching between two cell morphological states through GSK-3 activity. Cell reports, 44(3), 115361.

Rastogi S, et al. (2025) Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation. Cancer research communications, 5(4), 668.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. Cancer research, 85(11), 1978.

Bayet M, et al. (2025) Modeling the PAX5P80R Mutation Reveals HIF2? Activation as a Common Feature and Therapeutic Target in B-cell Acute Lymphoblastic Leukemia. Cancer research, 85(15), 2820.

Dussol M, et al. (2025) Contribution of peripheral and central delta opioid receptors in the relief of migraine-like headache in female and male rats. British journal of pharmacology, 182(18), 4380.

Esposito M, et al. (2025) Development of retinoid nuclear receptor pathway antagonists through targeting aldehyde dehydrogenase 1A3. iScience, 28(11), 113675.

Nie Z, et al. (2025) Structure-Based Discovery and Development of Highly Potent Dihydroorotate Dehydrogenase Inhibitors for Malaria Chemoprevention. Journal of medicinal chemistry, 68(1), 590.

Perez JM, et al. (2025) Investigating proteogenomic divergence in patient-derived xenograft models of ovarian cancer. Scientific reports, 15(1), 813.

Imai T, et al. (2025) Examination of Inter-? Inhibitor Proteins in Permanent and Transient Focal Ischemia. Journal of the American Heart Association, 14(4), e036034.